Are peptides legal in the EU?

How the rules work

EU medicines law starts from a definition, not a list. Directive 2001/83/EC treats as a medicinal product anything presented as treating or preventing disease, or that is administered to restore, correct or modify physiological functions. A peptide sold with claims about healing, fat loss or growth hormone meets the definition by presentation, whatever the label says about research. Article 6 then requires a marketing authorisation before any such product is placed on the market.

Authorisations for the peptides on LYO come through the EMA's centralised procedure: Ozempic (2018) and Wegovy (2022) for semaglutide, Mounjaro (2022) for tirzepatide, Victoza and Saxenda for liraglutide. Tesamorelin's EU application was withdrawn in June 2012 after the CHMP could not conclude a positive benefit–risk balance, and bremelanotide has never been filed. Retatrutide and cagrilintide are investigational and cannot be supplied outside clinical trials.

Enforcement is national. Each member state's medicines agency and customs service applies the directive through domestic law — Läkemedelsverket in Sweden, BfArM in Germany, ANSM in France — and coordinates through Europol. Operation SHIELD VI (April–November 2025, 30 countries) ended with 3,354 people prosecuted and €33 million of illicit medicines and doping substances seized.

Buying and importing for personal use

There is no EU-wide personal-import allowance; each country sets its own. Sweden is strict and typical of the north: a private person may receive medicines by post from another EEA country only for personal use, up to a year's supply, bought from a pharmacy, with a prescription where one is required, and only if the medicine is authorised both in Sweden and in the sending country. Receiving medicines by post from outside the EEA is not allowed at all, and Läkemedelsverket says it cannot grant exceptions. Since research peptides are authorised nowhere, none of them clears those conditions.

Other member states are looser in practice — customs in the Netherlands, Italy and Spain intercept less — but the legal position is the same everywhere: the seller commits an offence by supplying an unauthorised medicine, and the buyer has no consumer protection and no way to know what is in the vial.

Compound by compound

What changed, and when

1. 26 Jun 2012Egrifta (tesamorelin) marketing authorisation application withdrawn in the EU.
2. 2018 / 2022Ozempic and Wegovy (semaglutide) authorised; Mounjaro (tirzepatide) authorised 2022.
3. Apr–Nov 2025Europol Operation SHIELD VI: 3,354 prosecuted, €33 million seized across 30 countries.
4. 1 Jun 2026EMA's first guideline on the quality of synthetic peptide medicines takes effect — a manufacturing standard, not an authorisation route for research peptides.

Questions

Sources

1. 1
   Directive 2001/83/EC on the Community code relating to medicinal products for human use (Articles 1(2) and 6)eur-lex.europa.eu
2. 2
   Läkemedelsverket — Receiving medicines by post: rules for private individualsfragor.lakemedelsverket.se
3. 3
   Europol — Operation SHIELD VI results (3,354 prosecuted, €33 million seized)europol.europa.eu
4. 4
   EMA — Withdrawal of the marketing authorisation application for Egrifta (tesamorelin), 26 June 2012ema.europa.eu
5. 5
   Tullverket — Buying medicines online from another countrytullverket.se

LYO summarises the law for research and educational purposes. It is not legal advice; rules change and enforcement varies. Corrections through the contact page.